Novo Nordisk has announced a 40% reduction in the list price of Wegovy, its blockbuster weight loss injection, dropping the monthly cost from $1,350 to $810 as competition from Eli Lilly's Zepbound and approaching generic versions intensify market pressure.
Pricing Details
The price cut applies to all Wegovy dosages and takes effect May 1, 2026, with additional pharmacy benefit manager negotiations expected to reduce out-of-pocket costs further.
- New list price: $810/month (down from $1,350)
- Expected out-of-pocket with insurance: $200-$400/month
- Novo's patient assistance program: $0 copay for qualifying patients earning under $75,000
- Compounding pharmacy versions remain available at $200-$350/month
Market Dynamics
The price cut comes as Eli Lilly's Zepbound has captured 35% of the GLP-1 weight loss market with aggressive pricing and direct-to-consumer marketing. Analysts project that first generic semaglutide versions could reach the market by 2028, further pressuring branded pricing.
